Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis’ drugs might face stiff competition. So are investors being overly optimistic?
Source: The Motley Fool on finance and investing